Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Peripheral T-Cell Lymphomas: Therapeutic Approaches
David Sibon
Cancers (2022) Vol. 14, Iss. 9, pp. 2332-2332
Open Access | Times Cited: 19

Showing 19 citing articles:

Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
Pier Luigi Zinzani, Koji Izutsu, Neha Mehta‐Shah, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 12, pp. 1602-1613
Closed Access | Times Cited: 7
Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial
Laurence Brugières, Nathalie Cozic, Roch Houot, et al.
European Journal of Cancer (2023) Vol. 191, pp. 112984-112984
Open Access | Times Cited: 13
Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with peripheral T-cell lymphoma: a meta-analysis
Ying Wu, Yan Zhang
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
CMOEP regimen in the treatment of untreated peripheral T-cell lymphoma: a multicenter, single-arm, phase I study
Jingwei Yu, Xiuhua Sun, Guangxun Gao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
“Innate Immune Cell Engagers: Matchmakers for Next-Generation Immunotherapy”
Sascha Cording, Jens Pahl, Kristina Ellwanger, et al.
Springer eBooks (2025), pp. 1-25
Closed Access
Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology
Ariana Sabzevari, Johnson Ung, Jeffrey W. Craig, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access
Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin
Layla Veleanu, Laurence Lamant, David Sibon
New England Journal of Medicine (2024) Vol. 390, Iss. 22, pp. 2129-2130
Closed Access | Times Cited: 3
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study
Dai Maruyama, Eric D. Jacobsen, Pierluigi Porcu, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 12, pp. 1589-1601
Closed Access | Times Cited: 2
T cell receptor-directed antibody-drug conjugates for the treatment of T cell-derived cancers
Katrin Schoenfeld, Jan Habermann, Philipp Wendel, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200850-200850
Closed Access | Times Cited: 1
Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report
Vincent Camus, Pascaline Etancelin, Fanny Drieux, et al.
Clinical Case Reports (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 2
The Role of Epigenetic Modifier Mutations in Peripheral T-Cell Lymphomas
Adrian Bogdan Țigu, Anamaria Bancos
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 11, pp. 8974-8988
Open Access | Times Cited: 2
Sintilimab plus GemOx is an effective salvage therapy in patients with refractory⁄relapsing nodal peripheral T cell lymphomas
Xibin Xiao, Mengmeng Hu, Hua‐Wei Jiang, et al.
Research Square (Research Square) (2024)
Open Access
Advances in DNA Methylation in Peripheral T Cell Lymphoma
向慧 张
Advances in Clinical Medicine (2024) Vol. 14, Iss. 08, pp. 1181-1187
Closed Access
Sintilimab plus GemOx is an effective salvage therapy in patients with refractory/relapsing nodal peripheral T cell lymphomas
Xibin Xiao, Mengmeng Hu, Hua‐Wei Jiang, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 9
Open Access
Comparison of tucidinostat with CHOP-like versus CHOP-like in first-line treatment of peripheral T-cell lymphoma: a single-center real-world study
Xiaolian Wen, Tao Guan, Qinchuan Yu, et al.
Annals of Hematology (2024)
Closed Access
DL-ICE as a bridge to allogeneic transplantation in relapsed/refractory PTCL: survival outcomes and prognostic factors
Tong Yoon Kim, Tae Jung Kim, Eun Ji Han, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
MicroRNAs And Long Non-Coding RNAs In T-Cell Lymphoma: Mechanisms, Pathway, Therapeutic Opportunities
Mohammed H. Abu-Alghayth, Adil Abalkhail, Ali Hazazi, et al.
Pathology - Research and Practice (2024) Vol. 266, pp. 155769-155769
Closed Access
Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T‐cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report
Sigrid De Wilde, Carlos Graux
Clinical Case Reports (2024) Vol. 12, Iss. 7
Open Access
Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas
Marc Sorigué, Outi Kuittinen
Cancers (2022) Vol. 15, Iss. 1, pp. 220-220
Open Access | Times Cited: 2
Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: a case report
Vincent Camus, Pascaline Etancelin, Fanny Drieux, et al.
Authorea (Authorea) (2023)
Open Access
Page 1

Scroll to top